- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
InSite Vision, FDA discuss probable NDA for ocular anti-infective
InSite Vision representatives said they met recently with FDA officials to discuss sections of the proposed new drug application (NDA) submission for AzaSite, InSite's ocular anti-infective product. The drug is currently in late-stage development for the treatment of bacterial conjunctivitis.
InSite Vision representatives said they met recently with FDA officials to discuss sections of the proposed new drug application (NDA) submission for AzaSite, InSite's ocular anti-infective product. The drug is currently in late-stage development for the treatment of bacterial conjunctivitis.
The company said it anticipates launching AzaSite commercially in the United States in the second half of 2006, pending successful completion of and satisfactory results from current ongoing phase III clinical trials and subsequent filing of the full NDA and approval from the FDA.
